N
Patient 0
THE AUTOPSY REPORT PROVIDED BY THE CORONER INDICATES THAT THE FATALITY IS NOT LIKELY RELATED TO ANATOMICAL, HISTOLOGICAL, TOXICOLOGICAL OR MICROBIOLOGICAL CAUSES,WHILE SEROLOGY SUGGESTED LEVELS OF SERUM TRYPTASE INDICATIVE OF ACUTE ANAPHYLAXIS /TYPE1 HYPERSENSITIVITY, REFLECTING MAST CELL ACTIVATION. AS NOTED, THE PATHOLOGIST NOTED IN THE AUTOPSY REPORT THAT IF THERE WAS NO OTHER DRUG /TOXIN UNDER CONSIDERATION AS AN ALLERGEN, THE TOOTH MOUSSE /HYDROXYBENZOATE WAS A POTENTIAL /LIKELY CAUSE OF THE ANAPHYLAXIS. THE INSTRUCTIONS FOR USE (IFU) FOR GC TOOTH MOUSSE STATE THAT THE PRODUCT IS FOR USE BY OR UNDER THE SUPERVISION OF A DENTAL PROFESSIONAL IN THE RECOMMENDED INDICATIONS. THE CONTRAINDICATIONS LISTED IN THE IFU STATE: "DO NOT USE THIS MATERIAL ON PATIENTS WITH A PROVEN OR SUSPECTED MILK PROTEIN ALLERGY AND/OR WITH A SENSITIVITY OR ALLERGY TO BENZOATE PRESERVATIVES". GC TOOTH MOUSSE PROVIDES EXTRA PROTECTION FOR TEETH, HELPS NEUTRALIZE ACID CHALLENGES FROM ACIDOGENIC BACTERIA IN PLAQUE AND HELPS NEUTRALIZE ACID CHALLENGES FROM OTHER INTERNAL AND EXTERNAL SOURCES. THE IFU ALSO STATES UNDER THE CAUTION HEADING: "IF ANY ANGIOEDEMA SYMPTOMS ARE EXPERIENCED, THIS MAY INDICATE SENSITIVITY OR ALLERGY TO THE BENZOATE PRESERVATIVES, OR TO SOME OTHER COMPONENT OF THE PRODUCT SUCH AS A FLAVORING AGENT. IN THIS EVENT, DISCONTINUE THE USE OF THE PRODUCT AND REFER TO A PHYSICIAN". THE PRESENCE OF BENZOATES IS ALSO IDENTIFIED ON THE PACKAGING OF GC TOOTH MOUSSE, TOGETHER WITH A SIMILAR WARNING. THE CORONER HAS NOT PROVIDED DETAILS OF HOW THE DECEASED ACQUIRED GC TOOTH MOUSSE OR WHETHER OR NOT IT WAS USED UNDER THE SUPERVISION OF A DENTAL PROFESSIONAL FOR THE RECOMMENDED INDICATIONS. FURTHER, GC TOOTH MOUSSE DOES NOT CONTAIN EGGS OR EGG DERIVATIVES. THE INVESTIGATIONS ARE AT A VERY EARLY STAGE. THE IMMEDIATE ACTIONS TO BE UNDERTAKEN ARE AS FOLLOWS: THE INSTRUCTIONS FOR USE ( IFU) AND PACKAGING FOR GC TOOTH MOUSSE WILL BE CRITICALLY RE-EVALUATED WITHIN THE CONTEXT OF BOTH EUROPEAN AND U.S. REGULATORY REQUIREMENTS. PRODUCT RISK MANAGEMENT WILL BE RE-EVALUATED ACCORDINGLY AS WELL. INTERIM REPORT/FINAL REPORT IS EXPECTED TO BE AVAILABLE WITHIN TWO MONTHS. HOWEVER, THIS ESTIMATE MAY BE SUBJECT TO CHANGE DEPENDING ON THE OUTCOME OF THE CORONER'S ENQUIRIES AND/OR ANY INQUEST. GC TOOTH MOUSSE COMPLIES WITH ALL (B)(6) LAWS AND REGULATIONS CONCERNING THE MARKETING AND LABELING OF SUCH PRODUCTS IN (B)(6). IN THE U.S., THE DEVICE IS MARKETED AS AN RX DEVICE WITH THE BRAND NAME "MI PASTE," AND WAS GRANTED PREMARKET CLEARANCE BY FDA PURSUANT TO 510(K) K04220. OTHER THAN THE DIFFERENT BRAND NAMES BETWEEN THE (B)(6). AND THE U.S. PRODUCT (I.E., "TOOTH MOUSSE" IN THE (B)(6).;"MI PASTE" IN THE U.S.), THE LABELING, WARNINGS, INSTRUCTIONS AND PACKAGING ARE OTHERWISE IDENTICAL.